-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action --DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted in vitro data assessing the effects of EPA on lipoprotein(a) [Lp(a)] oxidation and on cellular stress and inflammatory protein expression in endothelial cells and preliminary data showcasing the potential anti-inflammatory mechanism of icosapent ethyl (IPE) via modulation of nod-like recepto ...

Investing in these pharmaceutical stocks is an easy decision.Some decisions require lengthy deliberations and extensive analysis. Others don't.Three Fool.com contributors think they've identified pharmaceutical stocks in the latter category. Here's why they think Pfizer (PFE 0.55%), Summit Therapeutics (SMMT -2.95%), and Vertex Pharmaceuticals (VRTX -0.23%) are no-brainer stocks to buy right now. Pfizer is a great option for both dividend and growth investorsDavid Jagielski (Pfizer): Pfizer is one of the bi ...

Core Viewpoint - The article emphasizes the importance of holding high-yield dividend stocks for the long term, highlighting five specific companies that demonstrate sustainability in their dividends and growth potential. Group 1: AbbVie - AbbVie has successfully navigated the patent cliff of its leading drug Humira, which previously accounted for over 60% of its sales, and continues to grow despite declining sales from this drug [3][4] - The company has invested in research and development and made strategic acquisitions, positioning itself for long-term success [4] - AbbVie is recognized as a Dividend King, having increased its dividend for 53 consecutive years, with a payout increase of 310% since its spin-off from Abbott Labs in 2013, currently yielding 3.16% [5] Group 2: Enbridge - Enbridge operates with a low-risk, utility-like business model, transporting 30% of North America's crude oil and 20% of the U.S. natural gas, making it a stable investment [7][8] - The company is the largest natural gas utility in North America and is investing in renewable energy, projecting $50 billion in growth opportunities through the end of the decade [8] - Enbridge has a forward dividend yield of 5.71% and has increased its dividend for 30 consecutive years [9] Group 3: Enterprise Products Partners - Enterprise Products Partners is a midstream energy leader with over 50,000 miles of pipeline, transporting various energy products [10] - Unlike Enbridge, it does not operate a natural gas utility and is structured as a limited partnership, which may involve tax complexities [11] - The company offers a high distribution yield of 6.82% and has increased its distribution for 27 consecutive years [11] Group 4: Realty Income - Realty Income has provided positive operational returns every year since its NYSE listing in 1994, supported by a diversified property portfolio with 1,630 clients across 91 industries [12][13] - The company employs a triple-net-lease business model, transferring most costs to tenants, and has significant growth opportunities in Europe [13] - Realty Income currently yields 5.55% and has increased its payout for 30 consecutive years [14] Group 5: Verizon Communications - Verizon is one of the largest wireless providers globally, benefiting from high entry barriers in the wireless network market [15] - Despite past performance challenges, the company is currently generating industry-leading wireless service revenue and has potential growth with the rollout of 6G networks by the end of the decade [16] - Verizon's dividend yield is 6.17%, and it has increased its dividend for 18 consecutive years, with expectations for continued growth [17]

格隆汇8月31日丨华润双鹤(600062.SH)公布，近日，公司全资子公司安徽双鹤药业有限责任公司(以下 简称"安徽双鹤")收到了国家药品监督管理局(以下简称"国家药监局")颁发的氯化钾注射液(以下简称"该 药品")《药品补充申请批准通知书》。 ...

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) who stayed on treatment1Similarly, the study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy® users compared with tirzepatide users in all treated people, regardless of any gaps in their treatment1This study adds to gro ...

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) who stayed on treatment1Similarly, the study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy® users compared with tirzepatide users in all treated people, regardless of any gaps in their treatment1This study adds to gro ...

Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company’s progress in its Phase 2 study targeting basal cell carcinoma — the most common form of skin cancer. Bokhari shared that over 75% of the 90 patients in the proof-of-concept trial have been randomized, with full enrollment expected by the end of the year. The study is investigating a novel, non-invasive treatment option. Bokhari confirmed that Medicus Pharma has requested a Type C meeting with the US Food and Drug Administ ...

V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1 85% of patients on Leqvio plus individually optimized lipid-lowering therapy (LLT) achieved LDL-C targets within 90 days vs. 31% of patients on placebo plus LLT1Patients on Leqvio plus LLT were 43% less likely to experience muscle-related adverse events compared to those on placebo plus LLT1 Basel, August 30, 2025 – ...

How does a 7.5% dividend yield sound?If you're in the market for some promising dividend-paying stocks, good for you! They can be powerful components in your portfolio, ideally delivering not only regular income but also, over time, appreciating stock prices.Dividends are often underappreciated by investors, especially those of us inclined to chase fast-growing high-flying stocks. But dividend-paying stocks are no slouches. Check out the table below and see if it doesn't surprise you. Dividend-Paying Status ...

Core Insights - The 2025 ESC/EAS Dyslipidemia Guideline Update reaffirms high-dose icosapent ethyl (IPE) as a Class IIA recommended therapy for high-risk or very high-risk patients to reduce cardiovascular events based on the REDUCE-IT trial findings [1][14] Group 1: REDUCE-IT Trial Findings - Three sub-analyses from the REDUCE-IT trial demonstrate significant reductions in cardiovascular disease (CVD) risk and outcomes associated with IPE administration in patients with cardiovascular-kidney-metabolic (CKM) syndrome, stratified by baseline apolipoprotein B (ApoB) and fasting triglyceride-rich lipoprotein cholesterol (TRL-C) levels [1][2] - IPE treatment showed a 44% relative risk reduction (RRR) for the primary composite endpoint in patients with an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², with a hazard ratio (HR) of 0.56 (95% CI 0.39, 0.79), P = 0.001, and an absolute risk reduction (ARR) of 11.2% [4][5] Group 2: Impact on Major Adverse Cardiovascular Events (MACE) - IPE treatment resulted in significant reductions in MACE across all quartiles of baseline ApoB and TRL-C concentrations, with HRs ranging from 0.72 to 0.80 for ApoB and from 0.74 to 0.68 for TRL-C, all with P ≤ 0.02 [8][9] Group 3: Hospitalization and Mortality Outcomes - IPE significantly reduced total hospitalizations (HR 0.91, 95% CI 0.84, 0.98, P=0.017) and increased the likelihood of surviving without hospitalization (odds ratio (OR) 1.12, 95% CI 1.02, 1.22, P=0.016) [12][13] Group 4: Clinical Recommendations - The ESC/EAS guidelines recommend high-dose IPE for patients with elevated triglyceride levels (135–499 mg/dL) despite statin therapy, emphasizing its role in reducing CVD events [14]